Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Oleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.72 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.72 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.72 |
| ▸ | PPARG | P37231 | 5/20 | 0.72 |
| ▸ | PPARD | Q03181 | 5/20 | 0.72 |
| ▸ | PPARA | Q07869 | 5/20 | 0.72 |
| ▸ | F7 | P08709 | 5/20 | 0.72 |
| ▸ | F3 | P13726 | 5/20 | 0.72 |
| ▸ | TERT | O14746 | 3/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | FABP4 | P15090 | 3/20 | 0.72 |
| ▸ | TOP1 | P11387 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleic Acid SCHEMBL1662962 | 1.00 | PPARG (0.72) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL23039156 | 0.92 | PPARG (0.60) | PPARGPPARDPPARAF7F3 | |
| Erucic Acid SCHEMBL30578789 | 0.92 | PPARG (0.60) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL3504903 | 0.92 | PPARG (0.60) | PPARGPPARDPPARAF7F3 | |
| Behenic Acid SCHEMBL28358014 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| Palmitic Acid SCHEMBL8514384 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| Myristic Acid SCHEMBL17054652 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| Stearic Acid SCHEMBL345023 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| Stearic Acid SCHEMBL30375325 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 | |
| Citric Acid SCHEMBL23644590 | 0.90 | GPR84 (0.65) | PPARGPPARDPPARAPTPN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2883536-A1 | Preparation of emulsions containing waxes in a cold process | Henkel AG & Co. KGaA (DE) | 2015-06-17 | — | — | EP | claimed |
| US-20240130957-A1 | EXTRACTS OF ISOCHRYSIS SPECIES/TISOCHRYSIS SPECIES | SYMRISE AG (DE) | 2024-04-25 | — | — | US | disclosed |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20230293406-A1 | Compositions Comprising (Bio)-Alkanediols and Cooling Agents | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| US-11723850-B2 | Liquid and transparent blend of UV filters | Symrise, AG (DE) | 2023-08-15 | — | — | US | disclosed |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230124050-A1 | Composition or oat extract comprising avenanthramide and ß-glucan | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230059747-A1 | A COOLING PREPARATION | SYMRISE AG (DE) | 2023-02-23 | — | — | US | disclosed |
| EP-4134426-A1 | NOVEL BACTERIAL FERMENT OF LACTOBACILLUS SPECIES | Symrise AG (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20220354775-A1 | NOVEL BACTERIAL FERMENT OF LACTOBACILLUS SPECIES | SYMRISE AG (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20120207731-A1 | METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME | KANEKA CORPORATION (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120121737-A1 | COMPOSITIONS COMPRISING TRANS-TERT-BUTYL CYCLOHEXANOL AS SKIN IRRITATION-REDUCING AGENT | SYMRISE AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20110091553-A1 | METHOD FOR PRODUCING MICROCAPSULES USING SOLID FAT | KANEKA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20100297222-A1 | METHOD FOR PRODUCTION OF MICROCAPSULES USING SOLID FAT | KANEKA CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2218446-A1 | METHOD FOR PRODUCING MICROCAPSULE USING SOLID FAT | Kaneka Corporation (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20100168249-A1 | COMPOSITION CONTAINING REDUCED COENZYME Q10, AND METHOD FOR STABILIZING THE COMPOSITION | KANEKA CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1641904-B1 | O/W EMULSIFIER, O/W EMULSION AND APPLICATIONS THEREOF | SYMRISE GMBH & CO KG (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1641904-A2 | O/W EMULSIFIER, O/W EMULSION AND APPLICATIONS THEREOF | Symrise GmbH & Co. KG (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004112731-A3 | O/W EMULSIFIER, O/W EMULSION AND APPLICATIONS THEREOF | SYMRISE GMBH & CO KG (DE) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004112731-A2 | O/W EMULSIFIER, O/W EMULSION AND APPLICATIONS THEREOF | SYMRISE GMBH & CO. KG (DE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059747-A1 | A COOLING PREPARATION | GPX4, HTR3C, ADH1C | ADORA3 1091/4885SLC6A2 265/4885FLT3 4740/4885 |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | CUTA, POLR1C, SLC16A7 | ADORA3 686/4885SLC6A2 1474/4885FLT3 3265/4885 |
| US-20230124050-A1 | Composition or oat extract comprising avenanthramide and ß-glucan | OAT, PIGS, HLA-A | ADORA3 700/4885SLC6A2 730/4885FLT3 1028/4885 |
| US-20230293406-A1 | Compositions Comprising (Bio)-Alkanediols and Cooling Agents | OR51E2, MAL2, ADH1C | ADORA3 2997/4885SLC6A2 3570/4885FLT3 4814/4885 |
| US-11723850-B2 | Liquid and transparent blend of UV filters | F2, F12, F10 | ADORA3 2789/4885SLC6A2 3368/4885FLT3 1400/4885 |
| US-20120121737-A1 | COMPOSITIONS COMPRISING TRANS-TERT-BUTYL CYCLOHEXANOL AS SKIN IRRITATION-REDUCING AGENT | TERT, CUTA, TRPA1 | ADORA3 3932/4885SLC6A2 3658/4885FLT3 4211/4885 |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | TACR1, NPSR1, TACR2 | ADORA3 116/4885SLC6A2 1019/4885FLT3 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.